Journal article · 2023 · Open access

Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study

Rasmus Westermann, René Cordtz, Kirsten Skjærbæk Duch, Lene Mellemkjær, Merete Lund Hetland, Andrea Michelle Burden, Lene Dreyer

Rheumatology, 63(1), 93–102 · Published 13 April 2023 · DOI 10.1093/rheumatology/kead163

Open PDFView at the publisherCite this paper

In brief

“Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study” is a 2023 journal article by Rasmus Westermann and 6 co-authors, published in Rheumatology. OpenAlex counts 33 citations as of 19 November 2026, which puts it in the top 7% of works published in 2023 by citations. It is open access: the full text is free to read at VBN Forskningsportal (Aalborg Universitet).

Citations
33
Most cited in
2025 (16)
Field-weighted impact
5.49
References
38
Authors
7

Abstract

OBJECTIVES: We aimed to investigate the risk of first primary cancer in patients with RA treated with janus kinase inhibitors (JAKi) compared with those who received biologic DMARDs (bDMARDs) in a real-world setting. METHODS: We performed an observational cohort study using the nationwide registers in Denmark. Patients with RA aged 18+ years, without a previous cancer diagnosis, and who initiated treatment with JAKi or bDMARDs from 1 January 2017 to 31 December 2020 were followed for any cancer (except non-melanoma skin cancer). We applied inverse probability of treatment weighting (IPTW) to account for covariate differences between treatment groups. IPTW-generated weights were used with cause-specific Cox (CSC) models to calculate hazard ratios (HRs) for cancer incidence in JAKi-treated compared with bDMARD-treated patients with RA. RESULTS: We identified 875 and 4247 RA patients treated with JAKi and bDMARDs, respectively. The JAKi group contributed 1315 person years (PYRS) and 19 cancers, the bDMARD group contributed 8597 PYRS and 111 cancers, with corresponding crude incidence rates per 1000 PYRS of 14.4 and 12.9. Comparing the two groups using weighted CSC models, a HR of 1.41 (95% CI 0.76, 2.37, 95% CIs) was seen for JAKi- vs bDMARD-treated patients with RA. CONCLUSION: JAKi treatment in real-world patients with RA was not associated with a statistically significant increased risk of first primary cancer compared with those who received bDMARDs. However, several numerically increased risk estimates were detected, and a clinically important excess risk of cancer among JAKi recipients cannot be dismissed.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Westermann, R., Cordtz, R., Duch, K. S., Mellemkjær, L., Hetland, M. L., Burden, A. M., & Dreyer, L. (2023). Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study. Rheumatology, 63(1), 93–102. https://doi.org/10.1093/rheumatology/kead163

MLA 9

Westermann, Rasmus, et al. “Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study.” Rheumatology, vol. 63, no. 1, 2023, pp. 93–102. https://doi.org/10.1093/rheumatology/kead163.

Chicago

Westermann, Rasmus, René Cordtz, Kirsten Skjærbæk Duch, Lene Mellemkjær, Merete Lund Hetland, Andrea Michelle Burden, and Lene Dreyer. 2023. “Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study.” Rheumatology 63 (1): 93–102. https://doi.org/10.1093/rheumatology/kead163.

Harvard

Westermann, R. et al. (2023) ‘Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study’, Rheumatology, 63(1), pp. 93–102. doi:10.1093/rheumatology/kead163.

IEEE

R. Westermann et al., “Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study,” Rheumatology, vol. 63, no. 1, pp. 93–102, 2023, doi: 10.1093/rheumatology/kead163.

BibTeX

@article{westermann2023cancer,
  title     = {{Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study}},
  author    = {Westermann, Rasmus and Cordtz, René and Duch, Kirsten Skjærbæk and Mellemkjær, Lene and Hetland, Merete Lund and Burden, Andrea Michelle and Dreyer, Lene},
  journal   = {Rheumatology},
  year      = {2023},
  volume    = {63},
  number    = {1},
  pages     = {93--102},
  doi       = {10.1093/rheumatology/kead163},
  url       = {https://doi.org/10.1093/rheumatology/kead163}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202322
202488
20251616
202677

Its field-weighted citation impact is 5.49: it has been cited 5.49 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • JAK inhibitors
  • biologic DMARDs
  • cancer risk
  • drug safety
  • non-melanoma skin cancer
  • inverse probability of treatment weighting

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Westermann, R., Cordtz, R., Duch, K. S., Mellemkjær, L., Hetland, M. L., Burden, A. M., & Dreyer, L. (2023). Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study. Rheumatology, 63(1), 93–102. https://doi.org/10.1093/rheumatology/kead163

How many times has this paper been cited?

33 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at VBN Forskningsportal (Aalborg Universitet): sign in and open the PDF from this page.

Who wrote this paper?

Rasmus Westermann, René Cordtz, Kirsten Skjærbæk Duch, Lene Mellemkjær, Merete Lund Hetland, Andrea Michelle Burden, Lene Dreyer.

What is the DOI of this paper?

10.1093/rheumatology/kead163, permanently at https://doi.org/10.1093/rheumatology/kead163. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.